Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction

CAI Tiantian; CHEN Junlong; ZHANG Yihang; HE Siyi; LIU Jian; XIAO Ruonan; LUO Shangjian; GAO Lei; ZHANG Dongying

doi:10.6039/j.issn.1001-0408.2026.08.13

您当前的位置：

首页 >

文章列表页 >

Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction

更新时间：2026-04-24

- Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction
- ZHONGGUO YAOFANG Vol. 37, Issue 8, Pages: 1045-1049(2026)
- 作者机构：
  
  1.重庆医科大学附属第一医院内分泌科，重庆　400042
  2.重庆医科大学附属第一医院心内科，重庆　400042
  3.重庆大学附属中心医院心内科，重庆　400010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.08.13
  CLC： R972
- Received：03 January 2026，
  
  Revised：2026-04-10，
  
  Accepted：10 April 2026，
  
  Published：30 April 2026
- 稿件说明：
移动端阅览
蔡恬恬,陈俊龙,张艺航,等.SGLT-2i在射血分数保留型心力衰竭患者中使用现状及影响因素的真实世界研究 [J].中国药房,2026,37(08):1045-1049.

CAI Tiantian,CHEN Junlong,ZHANG Yihang,et al.Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction[J].ZHONGGUO YAOFANG,2026,37(08):1045-1049.
蔡恬恬,陈俊龙,张艺航,等.SGLT-2i在射血分数保留型心力衰竭患者中使用现状及影响因素的真实世界研究 [J].中国药房,2026,37(08):1045-1049. DOI： 10.6039/j.issn.1001-0408.2026.08.13.

CAI Tiantian,CHEN Junlong,ZHANG Yihang,et al.Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction[J].ZHONGGUO YAOFANG,2026,37(08):1045-1049. DOI： 10.6039/j.issn.1001-0408.2026.08.13.

摘要

目的

探索钠-葡萄糖协同转运蛋白-2抑制剂（SGLT-2i）在真实世界射血分数保留型心力衰竭（HFpEF）患者中的使用现状及其影响因素。

方法

收集2023年5月至2024年5月在重庆医科大学附属第一医院住院的358例HFpEF患者资料，根据出院带药是否使用SGLT-2i，将患者分为SGLT-2i使用组和SGLT-2i未使用组。比较两组患者的基线特征、合并疾病及药物治疗差异，在单因素分析的基础上采用多因素Logistic回归分析筛选HFpEF患者使用SGLT-2i的独立影响因素，并进行分层分析。

结果

358例HFpEF患者中，SGLT-2i的总体使用率为33.5%。合并2型糖尿病[OR＝9.063，95%CI（4.924～16.679）

]

、合并房颤[OR＝3.135，95%CI（1.590～6.178）

]

、合并冠心病[OR＝1.888，95%CI（1.072～3.327）

]

以及使用袢利尿剂[OR＝3.822，95%CI（1.588～9.200）

]

均为HFpEF患者使用SGLT-2i的独立影响因素（

＜0.05）。分层描述结果与多因素分析结果一致，在合并2型糖尿病、房颤、冠心病及使用袢利尿剂的HFpEF患者中，SGLT-2i使用率更高（

＜0.05）；不同肾功能水平患者间的SGLT-2i使用率相近（

＞0.05）。

结论

真实世界中，HFpEF患者的SGLT-2i使用率较低，其治疗覆盖率仍需提升；该类药物在HFpEF患者中的使用主要受是否合并2型糖尿病、房颤、冠心病及袢利尿剂使用的影响。

Abstract

OBJECTIVE

To investigate the application and influencing factors of sodium-dependent glucose transporters 2 inhibitors（SGLT-2i） in patients with heart failure with preserved ejection fraction（HFpEF） in the real world.

METHODS

Data from 358 patients with HFpEF who were hospitalized at the First Affiliated Hospital of Chongqing Medical University from May 2023 to May 2024 were retrospectively collected. The patients were divided into the SGLT-2i group and the non-SGLT-2i group based on whether they were prescribed SGLT-2i upon discharge. Baseline characteristics， comorbidities， and differences in drug treatment were compared between the two groups. Based on univariate analysis， multivariate Logistic regression analysis was performed to identify independent influencing factors of SGLT-2i use in patients with HFpEF， followed by further stratified analysis.

RESULTS

Among 358 HFpEF patients， the overall utilization rate of SGLT-2i was 33.5%. Combined with type 2 diabetes [OR＝9.063，95%CI（4.924-16.679）

]

， atrial fibrillation [OR＝3.135，95%CI（1.590-6.178）

]

， coronary artery heart disease [OR＝1.888，95%CI（1.072-3.327）

]

and the use of loop diuretics [OR＝3.822， 95%CI （1.588-9.200）

]

were all independent influencing factors for the use of SGLT-2i in patients with HFpEF （

＜0.05）. The results of the stratified descriptive analysis were consistent with those of the multivariate analysis， showing a higher utilization rate of SGLT-2i among patients with concomitant T2DM，atrial fibrillation， coronary artery heart disease， and those receiving loop diuretics （

＜0.05）； whereas the utilization rate of SGLT-2i was comparable across patients with different levels of renal function （

＞0.05）.

CONCLUSIONS

In the real-world clinical practice， the utilization of SGLT-2i in patients with HFpEF remains suboptimal， and treatment coverage still needs to be improved. Their use of SGLT-2i is primarily influenced by the presence of type 2 diabetes， atrial fibrillation， coronary artery heart disease， and the use of loop diuretics.

关键词

Keywords

references

CAMPBELL P ， RUTTEN F H ， LEE M M ， et al . Heart failure with preserved ejection fraction：everything the clinician needs to know [J ] . Lancet ， 2024 ， 403 （ 10431 ）： 1083 - 1092 .

WAGDY K ， NAGY S . EMPEROR-Preserved：SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction [J ] . Glob Cardiol Sci Pract ， 2021 ， 2021 （ 3 ）： e202117 .

SOLOMON S D ， MCMURRAY J J V ， CLAGGETT B ， et al . Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction [J ] . N Engl J Med ， 2022 ， 387 （ 12 ）： 1089 - 1098 .

MCDONAGH T A ， METRA M ， ADAMO M ， et al . 2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J ] . Eur Heart J ， 2023 ， 44 （ 37 ）： 3627 - 3639 .

KITTLESON M M ， PANJRATH G S ， AMANCHERLA K ， et al . 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction a report of the American college of cardiology solution set oversight committee [J ] . J Am Coll Cardiol ， 2023 ， 81 （ 18 ）： 1835 - 1878 .

ZHANG Q ， FAN F ， YANG F ， et al . Disparities in SGLT2i utilization among heart failure patients with different ejection fraction in China：findings from Chinese Cardiovascular Association Database-Heart Failure Center registry [J ] . Eur Heart J ， 2024 ， 45 （ Suppl.1 ）：ehae666.1064.

STEVENS P E ， AHMED S B ， CARRERO J J ， et al . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J ] . Kidney Int ， 2024 ， 105 （ 4 ）： S117 - S314 .

PRATLEY R E ， CANNON C P ， CHERNEY D Z I ， et al . Cardiorenal outcomes，kidney function，and other safety outcomes with ertugliflozin in older adults with type 2 diabetes（VERTIS CV）：secondary analyses from a randomised，double-blind trial [J ] . Lancet Healthy Longev ， 2023 ， 4 （ 4 ）： e143 - e154 .

SHARMA A ， WOOD S ， BELL J S ， et al . Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes：a population-based cohort study [J ] . Lancet Reg Health West Pac ， 2023 ， 33 ： 100692 .

HEERSPINK H J L ， STEFANSSON B V ， CORREA-ROTTER R ， et al . Dapagliflozin in patients with chronic kidney disease [J ] . N Engl J Med ， 2020 ， 383 （ 15 ）： 1436 - 1446 .

ZHANG S Y . Chinese guidelines for the diagnosis and treatment of heart failure 2024 [J ] . J Geriatr Cardiol ， 2025 ， 22 （ 3 ）： 277 - 331 .

ABDEL JAWAD M ， SPERTUS J A ， IKEABA U ， et al . Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction [J ] . JAMA Cardiol ， 2025 ， 10 （ 1 ）： 89 .

DESAI A S ， LAM C S P ， MCMURRAY J J V ， et al . How to manage heart failure with preserved ejection fraction：practical guidance for clinicians [J ] . JACC Heart Fail ， 2023 ， 11 （ 6 ）： 619 - 636 .

GONZALEZ J ， DAVE C V . Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM，2013-2021 [J ] . BMC Cardiovasc Disord ， 2024 ， 24 （ 1 ）： 285 .

BORLAUG B A ， SHARMA K ， SHAH S J ， et al . Heart failure with preserved ejection fraction JACC scientific statement [J ] . J Am Coll Cardiol ， 2023 ， 81 （ 18 ）： 1810 - 1834 .

NEUEN B L ， FLETCHER R A ， ANKER S D ， et al . SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria：a meta-analysis [J ] . JAMA ， 2026 ， 335 （ 3 ）： 233 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of clinical characteristics and risk factors for infection in patients with multiple myeloma treated with bortezomib

Expert consensus on clinical application of parenteral direct thrombin inhibitors in perioperative period

Construction and application of anti-tumor drug prescription review decision-support system in a large general hospital

Expert consensus on the medication catalog for drug-induced liver injury and rational drug use

Analysis of the application status of prescription pre-review systems in Yunnan province

Related Author

JIANG Wenting

ZHOU Jie

LYU Bo

SHI Aiming

LI Bingzong

PAN Jie

JIANG Mingyu

BIAN Yuan

Related Institution

Dept. of Hematology， the Second Affiliated Hospital of Soochow University

Dept. of Pharmacy， the Second Affiliated Hospital of Soochow University

Dept. of Pharmacy， the First Affiliated Hospital of Chengdu Medical College

Dept. of Pharmacy/Personalized Drug Research and Therapy Key Laboratory of Sichuan Province， Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital （the Affiliated Hospital of UESTC）

School of Pharmacy， North Sichuan Medical College， Sichuan Nanchong

⁰